American Journal of Veterinary Research · 2011 · 13 citations · 29 references
MedicineCancer BiologyOncologyApoptosisCarcinogenesisMolecular OncologyMalignant NeoplasmsOral Cancer PathologyOral CarcinogenesisSquamous Cell Carcinoma5-Lipoxygenase Activation5-Lipoxygenase InhibitionAnnexin V AssaysFeline Cancer ModelsFeline Squamous Cell CarcinomaImmunohistochemical StainingLipoxygenase InhibitionParaffin-embedded Tissue Staining
OBJECTIVE: To assess expression pattern and subcellular compartmentalization of 5-lipoxygenase in cutaneous, UV radiation-induced, and oral squamous cell carcinomas (SCCs) in cats and determine the effects of cyclooxygenase or 5-lipoxygenase inhibition on proliferation or apoptosis in a feline oral squamous cell carcinoma (SCCF1) cell line. SAMPLE: 60 archived paraffin-embedded samples of SCCs from 60 cats and SCCF1 cells. PROCEDURES: Retrospective immunohistochemical analysis of the archived samples of SCCs (20 cutaneous, 20 UV radiation-induced, and 20 oral tumors) was performed. Cell culture proliferation assays involving SCCF1 cells were performed, and tepoxalin-induced apoptosis and signaling were examined via western blotting and annexin V staining. RESULTS: Immunohistochemically, staining for 5-lipoxygenase was most frequently of greatest intensity in oral SCCs, whereas staining of cutaneous and UV radiation-induced lesions had less consistent 5-lipoxygenase expression. Exposure of SCCF1 cells to the 5-lipoxygenase inhibitor tepoxalin resulted in apoptosis; the effect appeared to be mediated via alteration of cell signaling rather than via suppression of lipid mediators that are typically produced as a result of 5-lipoxygenase activity. CONCLUSIONS AND CLINICAL RELEVANCE: In cats, expression of 5-lipoxygenase in SCCs appeared to differ depending on tumor location. The influence of tepoxalin-induced 5-lipoxygenase inhibition on a 5-lipoxygenase-expressing cell line coupled with the notable expression of 5-lipoxygenase in oral SCCs suggested that 5-lipoxygenase inhibition may have therapeutic benefits in affected cats. Although the safety of tepoxalin in cats has yet to be investigated, 5-lipoxygenase inhibitors should be evaluated for use as a potential treatment for SCCs in that species.
29
Dennis Argentieri, Dave M. Ritchie, Michael P. Ferro et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 133 citations
Anna J. Duffield‐Lillico, Jay O. Boyle, Xi Kathy Zhou et al. · Cancer Prevention Research · 2009 · 112 citations · Full text